Contineum Therapeutics (CTNM) Competitors $10.91 +0.41 (+3.90%) Closing price 04:00 PM EasternExtended Trading$10.86 -0.05 (-0.50%) As of 04:39 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CTNM vs. NTLA, TLRY, SNDX, EVO, STOK, AMPH, RCUS, GPCR, PHVS, and TRMLShould you be buying Contineum Therapeutics stock or one of its competitors? The main competitors of Contineum Therapeutics include Intellia Therapeutics (NTLA), Tilray Brands (TLRY), Syndax Pharmaceuticals (SNDX), Evotec (EVO), Stoke Therapeutics (STOK), Amphastar Pharmaceuticals (AMPH), Arcus Biosciences (RCUS), Structure Therapeutics (GPCR), Pharvaris (PHVS), and Tourmaline Bio (TRML). These companies are all part of the "pharmaceutical products" industry. Contineum Therapeutics vs. Its Competitors Intellia Therapeutics Tilray Brands Syndax Pharmaceuticals Evotec Stoke Therapeutics Amphastar Pharmaceuticals Arcus Biosciences Structure Therapeutics Pharvaris Tourmaline Bio Contineum Therapeutics (NASDAQ:CTNM) and Intellia Therapeutics (NASDAQ:NTLA) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability. Does the media refer more to CTNM or NTLA? In the previous week, Intellia Therapeutics had 11 more articles in the media than Contineum Therapeutics. MarketBeat recorded 17 mentions for Intellia Therapeutics and 6 mentions for Contineum Therapeutics. Contineum Therapeutics' average media sentiment score of 0.78 beat Intellia Therapeutics' score of 0.69 indicating that Contineum Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Contineum Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intellia Therapeutics 5 Very Positive mention(s) 1 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is CTNM or NTLA more profitable? Contineum Therapeutics has a net margin of 0.00% compared to Intellia Therapeutics' net margin of -908.48%. Contineum Therapeutics' return on equity of -29.75% beat Intellia Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Contineum TherapeuticsN/A -29.75% -28.08% Intellia Therapeutics -908.48%-57.48%-45.04% Which has better earnings & valuation, CTNM or NTLA? Contineum Therapeutics has higher earnings, but lower revenue than Intellia Therapeutics. Contineum Therapeutics is trading at a lower price-to-earnings ratio than Intellia Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioContineum Therapeutics$50M6.12-$42.26M-$2.20-4.96Intellia Therapeutics$52.86M33.73-$519.02M-$4.69-3.54 Do analysts rate CTNM or NTLA? Contineum Therapeutics currently has a consensus price target of $22.20, suggesting a potential upside of 103.48%. Intellia Therapeutics has a consensus price target of $27.39, suggesting a potential upside of 64.89%. Given Contineum Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Contineum Therapeutics is more favorable than Intellia Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Contineum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 3.14Intellia Therapeutics 1 Sell rating(s) 7 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.53 Which has more volatility and risk, CTNM or NTLA? Contineum Therapeutics has a beta of 1.19, indicating that its share price is 19% more volatile than the S&P 500. Comparatively, Intellia Therapeutics has a beta of 2.28, indicating that its share price is 128% more volatile than the S&P 500. Do insiders & institutionals believe in CTNM or NTLA? 88.8% of Intellia Therapeutics shares are held by institutional investors. 11.3% of Contineum Therapeutics shares are held by company insiders. Comparatively, 3.1% of Intellia Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryContineum Therapeutics beats Intellia Therapeutics on 10 of the 17 factors compared between the two stocks. Get Contineum Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CTNM and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CTNM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CTNM vs. The Competition Export to ExcelMetricContineum TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$305.92M$3.07B$5.65B$10.30BDividend YieldN/A2.36%5.68%4.62%P/E Ratio-4.9620.7675.8426.11Price / Sales6.12403.88517.39171.57Price / CashN/A45.9137.5661.52Price / Book1.429.6212.876.30Net Income-$42.26M-$52.73M$3.29B$271.03M7 Day Performance-12.02%0.65%-0.26%-0.14%1 Month Performance5.00%6.32%3.85%6.42%1 Year Performance-40.02%18.97%68.36%28.81% Contineum Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CTNMContineum Therapeutics2.5113 of 5 stars$10.91+3.9%$22.20+103.5%-44.2%$305.92M$50M-4.9631News CoverageAnalyst ForecastGap UpNTLAIntellia Therapeutics4.4412 of 5 stars$12.35+6.7%$27.11+119.6%-17.3%$1.33B$52.86M-2.65600TLRYTilray Brands2.6389 of 5 stars$1.20+1.3%$1.94+62.1%-26.7%$1.32B$210.48M-0.522,842Gap DownSNDXSyndax Pharmaceuticals3.9194 of 5 stars$15.16-4.3%$39.22+158.8%-17.9%$1.31B$23.68M-3.90110EVOEvotec1.5894 of 5 stars$3.67+4.9%$5.40+47.1%+10.1%$1.30B$777.33M0.004,827Gap DownSTOKStoke Therapeutics3.9125 of 5 stars$23.41+0.0%$25.57+9.2%+77.7%$1.28B$199.89M27.51100Positive NewsAMPHAmphastar Pharmaceuticals4.3248 of 5 stars$27.29+0.1%$31.60+15.8%-43.3%$1.27B$731.97M10.232,028Positive NewsRCUSArcus Biosciences1.6314 of 5 stars$11.72+1.2%$21.14+80.4%-19.6%$1.25B$262M-3.71500Positive NewsGPCRStructure Therapeutics2.9886 of 5 stars$21.54+6.6%$75.71+251.5%-41.8%$1.24BN/A-20.58136Positive NewsPHVSPharvaris2.3302 of 5 stars$23.52+0.6%$34.00+44.6%+28.6%$1.23BN/A-7.0330TRMLTourmaline Bio0.9382 of 5 stars$47.70+0.1%$45.65-4.3%+102.8%$1.23BN/A-13.9144Positive News Related Companies and Tools Related Companies NTLA Competitors TLRY Competitors SNDX Competitors EVO Competitors STOK Competitors AMPH Competitors RCUS Competitors GPCR Competitors PHVS Competitors TRML Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CTNM) was last updated on 9/25/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredA New Way to Double Your Retirement Income?Bloomberg reports that a new class of investments is “entering a golden era,” with yields fueling a retail boo...Investors Alley | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredMusk’s Project Colossus could mint millionairesI predict this single breakthrough could make Elon the world’s first trillionaire — and mint more new milliona...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Contineum Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Contineum Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CTNM Stock Alerts